 "JM Hegde, managing director (MD), Biorad Medisys")
In what could be a breakthrough in diabetes management, Pune-based medical-device manufacturer Biorad Medisys, which recently acquired a portion of US-based ReShape Lifesciences’ assets, is developing an implantable device that uses vagus nerve stimulation (VNS) technology to help manage blood-glucose levels, improve insulin sensitivity and secretion, regulate hunger, and thereby reduce obesity.
“This is going to be like a path breaker…. If you look at GLP-1 class of drugs, they have given very good results, but one does not know how many dropouts will happen in the next few years,” J M Hegde, managing director of Biorad Medisys, told Business
